Scribe Therapeutics Inc. (SCTX)
NASDAQ: SCTX · Real-Time Price · USD
28.05
-4.95 (-15.00%)
Sep 21, 2026, 4:00 PM EDT - Market closed
Scribe Therapeutics Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Scribe Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $57. The average 1-year stock price forecast is 103.21% higher than the current stock price, while the lowest is $50 (+78.25%) and the highest is $60 (+113.90%).
Price Target: $57 (+103.21%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Scribe Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $60 | Buy | Reiterates | $60 | +113.90% | Sep 3, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $60 | Buy | Maintains | $60 | +113.90% | Aug 31, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $37 | Buy | Initiates | $37 | +31.91% | Aug 18, 2026 |
| Guggenheim | Guggenheim | Buy Initiates $50 | Buy | Initiates | $50 | +78.25% | Aug 18, 2026 |
Financial Forecast
Revenue This Year
11.57M
from 51.17M
Decreased by -77.39%
Revenue Next Year
6.73M
from 11.57M
Decreased by -41.82%
EPS This Year
-5.59
EPS Next Year
-3.62
from -5.59
EPS and Forward PE are based on non-GAAP adjusted numbers.